Nonetheless, ICI-mediated tumor therapy targeting CTLA-4 is infrequently applied in clinical setting because it shows delayed effects and is sometimes associated with severe side effects, including hepatitis, colitis, and thyroiditis, owing to overactive immune responses [94,121]. This evidence concerns the gene CTLA4 and neoplasm.